Ainos Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
AIMD Nasdaq 8731 http://www.ainos.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Ainos Inc

Ainos and Tah-An Sign MoU to Explore Manufacture of VELDONA Animal Investigational New Drug - Jan 23rd, 2023 12:00 pm
Ainos Issues 2023 Shareholder Letter - Jan 17th, 2023 12:00 pm
Ainos Publishes Preclinical Data Demonstrating its VELDONA Formulation's Potential as Treatment Candidates for the Most Common Medical Conditions for Companion Animals - Nov 21st, 2022 10:30 am
Ainos Reports Unaudited Third Quarter 2022 Financial Results - Nov 7th, 2022 12:30 pm
Five New Drug Candidates Show Promise as Ainos Pursues Licensing Partners of its Low-dose Oral Interferon Formulation - Nov 3rd, 2022 11:00 am
Ainos Pursues Licensing Partners to Accelerate Five Candidates of its Low-dose Oral Interferon Formulation VELDONA to Phase 3 Trials and Commercialization - Oct 31st, 2022 11:00 am
Ainos Announces Positive Results from Additional Preclinical Study of Its Low-dose Oral Interferon Formulation Against New Variant Virus - Omicron - Sep 30th, 2022 11:00 am
Ainos Submits Investigational New Drug Application to the U.S. FDA to Conduct Phase 2 Trial of its VELDONA Low-dose Oral Interferon Formulation Against Mild COVID-19 Symptoms - Aug 24th, 2022 11:00 am
Ainos Announces Master Services Agreement with Swiss Pharmaceutical, Ltd. for Drug Testing, Manufacturing, and Packaging for its VELDONA Product Candidates - Aug 17th, 2022 12:05 pm
Ainos Reports Second Quarter 2022 Financial Results - Aug 15th, 2022 11:20 am
Ainos Announces Closing of $3.3 Million Public Offering, Uplisting to NASDAQ, and Reverse Stock Split - Aug 11th, 2022 6:12 pm
How Much Of Ainos, Inc. (NASDAQ:AIMD) Do Insiders Own? - Aug 10th, 2022 1:20 pm
Ainos Announces Pricing of $3.3 Million Public Offering, Uplisting to NASDAQ, and Reverse Stock Split - Aug 9th, 2022 12:57 am
Ainos Announces Positive Results from Preclinical Studies of Its Low-dose Oral Interferon Formulation Against COVID-19 - Jun 27th, 2022 11:00 am
Ainos COVID-19 Antigen Self-Test Receives Approval for Sale in Taiwan - Jun 21st, 2022 11:00 am